Ask AI
Oral Therapies in HR Positive HER2 Negative Breast Cancer

CE

Targeted Therapy Advances in HR+/HER2- Breast Cancer: Best Practices for Oncology Pharmacists

Pharmacists: 0.50 contact hour (0.05 CEUs)

Released: July 31, 2026

Expiration: January 30, 2027

Activity

Progress
1 2 3
Course Completed

References

  1. National Comprehensive Cancer Network. Clinical practice guidelines in oncology: breast cancer. v.3.2026. nccn.org. Accessed July 27, 2026.
  2. Fan W, Chang J, Fu P. Endocrine therapy resistance in breast cancer: current status, possible mechanisms and overcoming strategies. Future Medicinal Chemistry. 2015;7:1511-1519.
  3. Garutti M, Griguolo G, Botticelli A, et al. Definition of high-risk early hormone-positive HER2−negative breast cancer: a consensus review. Cancers. 2022;14:1989.
  4. Pan H, Gray R, Braybrooke J, et al. 20-year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years. N Engl J Med. 2017;377:1836-1846.
  5. Pan H, Braybrooke J, Gray R, et al. Improvements in long-term outcome for women with estrogen receptor positive (ER+) early stage breast cancer treated with 5 years of endocrine therapy: Analyses of 82,598 women in the Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) database. Presented at: 2019 San Antonio Breast Cancer Symposium. December 10-14, 2019. Abstract GS2-04.
  6. Johnston S, Martin M, J O'Shaughnessy, et al. Overall survival with abemaciclib in early breast cancer. Ann Oncol. 2026;37:155-165.
  7. Crown J, Stroyakovskii D, Yardley DA, et al. Adjuvant ribociclib plus nonsteroidal aromatase inhibitor therapy in patients with HR-positive/HER2-negative early breast cancer: 5-year follow-up of NATALEE efficacy outcomes and updated overall survival. ESMO Open. 2025;10:105858.
  8. O’Shaughnessy J, Brezden-Masley C, Cazzaniga M, et al. Prevalence of germline BRCA mutations in HER2-negative metastatic breast cancer: global results from the real-world, observational BREAKOUT study. Breast Cancer Res. 2020;22:114.
  9. Geyer CE, Garber JE, Gelber RD, et al. Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer. Ann Oncol. 2022;33:1250-1268.
  10. Garber J, Cameron D, Campbell C, et al. OlympiA: A phase 3, multicenter, randomized, placebo-controlled trial of adjuvant olaparib after (neo)adjuvant chemotherapy in patients w/ germline BRCA1 & BRCA2 pathogenic variants & highrisk HER2-negative primary breast cancer. Presented at: 2024 San Antonio Breast Cancer Symposium. December 10-13, 2024. Abstract GS1-09.
  11. Turner NC, Kingston B, Kilburn LS, et al.  Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial. Lancet Oncol. 2020;21:1296-1308.
  12. Pessoa LS, Heringer M, Ferrer VP. ctDNA as a cancer biomarker: A broad overview. Crit Rev Oncol Hematol. 2020;155:103109.
  13. Burstein HJ, DeMichele A, Somerfield, MR, et al. Testing for ESR1 mutations to guide therapy for hormone receptor–positive, human epidermal growth factor receptor 2–negative metastatic breast cancer: ASCO guideline rapid recommendation update. J Clin Oncol. 2023;41:3423-3425.
  14. Xi J, Ma CX, O’Shaughnessy J. Current clinical utility of circulating tumor DNA testing in breast cancer: a practical approach. JCO Oncol Pract. 2024;20:1460-1470.
  15. Jhaveri KL, Im SA, Saura C, et al. Overall survival with inavolisib in PIK3CA-mutated advanced breast cancer. N Engl J Med. 2025;393:151-161.
  16. Turner NC, Oliveira M, Howell SJ, et al. Capivasertib in hormone receptor-positive advanced breast cancer. N Engl J Med. 2023;388:2058-2070.
  17. Rugo HS, Oliveira M, Howell SJ, et al. Capivasertib (C) and fulvestrant (F) for patients (pts) with HR+/HER2− advanced breast cancer (ABC): Final overall survival (OS) results from the phase III CAPItello-291 trial. Presented at: 2026 European Society for Clinical Oncology (ESMO) Breast Cancer Annual Congress. May 6-8, 2026. Abstract 417O.
  18. Food and Drug Administration. FDA approves gedatolisib with fulvestrant, with or without palbociclib, for HR-positive, HER2-negative locally advanced or metastatic breast cancer. fda.gov/drugs/resources-information-approved-drugs/fda-approves-gedatolisib-fulvestrant-or-without-palbociclib-hr-positive-her2-negative-locally. Accessed July 27, 2026.
  19. Hortobagyi GN, Stemmer SM, Burris HA, et al. Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer. Ann Oncol. 2018;29:1541-1547.
  20. Bidard FC, Kaklamani VG, Neven P, et al. Elacestrant (oral selective estrogen receptor degrader) versus standard endocrine therapy for estrogen receptor–positive, human epidermal growth factor receptor 2–negative advanced breast cancer: results from the randomized phase III EMERALD trial. J Clin Oncol. 2022;40:3246-3256.
  21. Bardia A, Cortés J, Bidard FC, et al. Elacestrant in ER+, HER2– MBC with ESR1-mutated tumors: subgroup analyses from the phase III EMERALD trial by prior duration of endocrine therapy plus CDK4/6 inhibitor and in clinical subgroups. Clin Cancer Res. 2024;30:4299-4309.
  22. Jhaveri KL, Neven P, Casalnuovo ML, et al. Imlunestrant with or without abemaciclib in advanced breast cancer. N Engl J Med. 2025;393:1189-1202.
  23. Jhaveri KL, Neven P, Casalnuovo ML, et al. Imlunestrant with or without abemaciclib in advanced breast cancer: updated efficacy results from the phase 3 EMBER-3 trial. Ann Oncol. 2026;37:532-543.
  24. Vepdegestrant [prescribing information]. New Haven, CT: Arvinas, Inc.; 2026.
  25. Campone M, De Laurentiis M, Jhaveri K, et al. Vepdegestrant, a PROTAC estrogen receptor degrader, in advanced breast cancer. N Engl J Med. 2025;393:556-568.